LIVE WEBINARS: July 7, July 14 and July 21, 2020, 12:00 PM – 1:00 PM ET

Meet The Professors: Clinical Investigators Discuss Existing and Emerging Treatment Strategies for Patients with Ovarian, Cervical and Endometrial Cancer

A Virtual CME Webinar Series

Research To Practice is pleased to offer these complimentary CME-certified 1-hour virtual sessions on 4 different dates. Each session will be moderated by Dr Neil Love and feature 2 renowned clinical investigators with expertise in ovarian, cervical and endometrial cancer. An additional session is to be announced.

Session Dates

14
JULY
Michael J Birrer, MD, PhD and Kathleen Moore, MD
Tuesday 12:00 PM – 1:00 PM ET | Webinar
21
JULY
Joyce F Liu, MD, MPH and David M O’Malley, MD
Tuesday 12:00 PM – 1:00 PM ET | Webinar

Previous Event

7
JULY
Robert L Coleman, MD and Ursula Matulonis, MD

There is no registration fee for these events.

All events moderated by:
Neil Love, MD
Research To Practice
Miami, Florida

Tuesday, July 7, 2020 from 12:00 PM to 1:00 PM ET

Robert L Coleman, MD
Chief Scientific Officer
US Oncology Research
Gyencologic Oncology
McKesson
The Woodlands, Texas
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Masschusetts

Tuesday, July 14, 2020 from 12:00 PM to 1:00 PM ET

Michael J Birrer, MD, PhD
Director
Winthrop P Rockefeller Cancer Institute
Director
Cancer Service Line
University of Arkansas
Little Rock, Arkansas
Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair
in Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Tuesday, July 21, 2020 from 12:00 PM to 1:00 PM ET

Joyce F Liu, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director
Gynecologic Oncology Phase I Program
The Ohio State University and the
James Cancer Center
Columbus, Ohio

Topics to Be Discussed

  • Genetic testing in ovarian cancer (OC) and biologic basis for the use of PARP inhibitors
  • Integration of PARP inhibitor maintenance therapy into the management of newly diagnosed OC
  • Potential role of PARP inhibitors with chemotherapy; other investigational combination approaches in clinical development for advanced OC
  • Emerging role of immune checkpoint inhibitor therapy for endometrial cancer
  • Current indications for and future role of immune checkpoint inhibitors in cervical cancer
  • Potential role of immune checkpoint inhibitor therapy in the management of OC
  • Novel targeted agents and strategies under investigation for gynecologic cancers

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Consider the FDA approvals of and available data with olaparib, olaparib/bevacizumab and niraparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer, and counsel appropriate patients regarding treatment recommendations.
  • Appreciate the biologic rationale for and available data with the use of PARP inhibitors in combination with chemotherapy, and discern how these therapeutic approaches may affect treatment algorithms in the future.
  • Assess available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory ovarian cancer in order to design personalized care plans potentially incorporating these agents.
  • Describe the biologic rationale for, published research data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with other targeted agents for gynecologic cancers, and identify patients who may be eligible for this strategy.
  • Recognize the toxicities associated with PARP inhibitors, immune checkpoint inhibitors and novel agents currently in use or under investigation for gynecologic cancers, and offer supportive management strategies to minimize or ameliorate these side effects.
CME Credit Formt
A CME credit form link will be emailed to each participant within 24 hours after the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Birrer: Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company. Dr Coleman: Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Liu: Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Contracted Research: Agenus Inc, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, Genentech, a member of the Roche Group, Oncology Venture A/S, Regeneron Pharmaceuticals Inc, Surface Oncology, Tesaro, A GSK Company, Vigeo Therapeutics. Dr Matulonis: Advisory Committee and Consulting Agreement: Novartis. Dr Moore: Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Aravive Inc, Clovis Oncology, Eisai Inc, Genentech, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners. Dr O’Malley: Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seattle Genetics, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Botherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seattle Genetics, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

Supporters
These activities are supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Seattle Genetics and Tesaro, A GSK Company.